Infectious Etiology of Alzheimer's Disease (R01 Clinical Trial Optional) (RFA-AG-21-034)

Sponsor: National Institute on Aging

Award: NIA intends to commit $6 million in FY2021 to fund eight to 10 awards.

Due Date: March 31, 2021

Early Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed) (PAR-21-109)

Sponsor: National Institutes of Health

Due Date: Standard dates apply. The first application due date for this FOA is June 16, 2021.

Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required) (RFA-TR-21-010)

Sponsor: National Center for Advancing Translational Sciences

Due Date: April 13, 2021, September 13, 2021, January 12, 2022

Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey (UG3/UH3 Clinical Trial Optional) (RFA-TR-21-008)

Sponsor: National Center for Advancing Translational Sciences

Award: NCATS intends to commit a total of $1 million per year for FY2022-2026 to fund up to three awards.

Due Date: April 19, 2021

BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed) (RFA-EY-21-001)

Sponsor: National Institutes of Health

Award: NIH intends to fund an estimated 10 awards per fiscal year, corresponding to a total of $3-4 million in new awards per year.

Due Date: May 3, 2021; October 29, 2021; May 2, 2022; October 28, 2022; May 1, 2023; October 27, 2023

2022 Neurobiology of Brain Disorders Award

Sponsor: The McKnight Endowment Fund for Neuroscience

Award: Up to four awards are made annually, each providing $100,000 per year for three years.

Due Date: LOIs are due on March 15, 2021 (midnight in the last time zone on earth). Full proposals will be due September 20, 2021. Funding begins on February 1, 2022.

Regulation of Brain Regional and Cell Type Specific Proteome Dynamics in Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed) (RFA-AG-21-033)

Sponsor: National Institute on Aging

Award: NIA intends to commit $8.5 million in FY 2021 to fund six to eight awards.

Due Date: March 18, 2021

New Approaches to Identify Neurogenesis and Study its Dynamics in Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed) (RFA-AG-22-006)

Sponsor: National Institute on Aging

Award: NIA intends to commit $6.4 million in FY 2022 to fund eight to 10 awards.

Next Generation Sequencing in Post Mortem Tissue from Patients with Parkinsons Disease (U01 Clinical Trial Not Allowed) (RFA-NS-21-017)

Sponsor: National Institute of Neurological Disorders and Stroke

Award: NINDS intends to commit $2 million in FY 2021 to fund one award.

Due Date: March 15, 2021

Music and Health: Understanding And Developing Music Medicine (R21 Clinical Trial Optional) (PAR-21-099)

Sponsor: National Institutes of Health

Due Date: February 16, 2021; February 16, 2022; February 16, 2023

Music and Health: Understanding And Developing Music Medicine (R01 Clinical Trial Optional) (PAR-21-100)

Sponsor: National Institutes of Health

Due Date: February 5, 2021; February 5, 2022; February 5, 2023

International Research Grant Program: June 2021 Program

Sponsor: Alzheimer's Association

Award: Varies from $150,000 to $450,000

Due Date: Letter of Intent due by 5 p.m. EST, January 31, 2021

Notice of Special Interest (NOSI): Sensory and Motor System Changes as Predictors of Preclinical Alzheimers Disease (NOT-AG-20-053)

Sponsor: National Institute on Aging

Award: March 11, 2021

Limited Competition: National Institute on Aging (NIA) Late Onset of Alzheimers Disease (LOAD) Family-Based Study (FBS) (U24 Clinical Trial Not Allowed) (RFA-AG-22-001)

Sponsor: National Institute on Aging

Award: NIA intends to commit $3.5 million

Due Date: February 17, 2021

Treat FTD Fund

Sponsor: The Association for Frontotemporal Degeneration

Award: Up to $2 million

Due Date: February 5, 2021: LOIs due